Amgen Stock Edges Near Analyst Targets on Solid Fundamentals
Amgen stock is trading near its analyst target price of approximately USD 387.69 as of mid-September 2026, according to MarketScreener. The stock closed at USD 385.65 on Nasdaq on September 18, 2026, leaving a limited upside of about USD 2.04 or roughly 0.5% below the average target.
The recent earnings momentum supports Amgen's stock performance, with financial portals characterizing its earnings as beats versus market expectations. This has contributed to the company's strong record of dividend growth, which matters for income-oriented investors assessing large-cap healthcare names.
A recent overview of healthcare dividend payers lists Amgen alongside peers such as AbbVie with a dividend growth grade of A-, indicating that the company has consistently increased its payout over time and compares favorably within the sector, according to Seeking Alpha on September 21, 2026. The market has already priced in much of the expected earnings and dividend story, yet leaves room for additional upside if Amgen continues to deliver above-consensus results and maintains its dividend growth trajectory.